SunAct

What SunAct does

SunAct (legal entity: SunAct Cancer Private Limited) is a privately held Indian specialty cancer treatment center founded in 2010 and headquartered in Thane, Maharashtra, operating a second facility in Khar, Mumbai. The company delivers advanced hematological and oncological therapies to patients across India, with a service portfolio spanning six core offerings: autologous CAR T-cell therapy, bone marrow and stem cell transplantation (BMT), immunotherapy, targeted therapy, chemotherapy, and pediatric hematology-oncology including pediatric BMT and cellular therapy. Treatment is delivered through state-of-the-art hospital facilities equipped with specialized isolation rooms required for transplants and advanced cellular therapies. The business is co-founded and clinically led by Dr. (Prof.) Vijay Patil, a medical oncologist with 800+ peer-reviewed publications and over two decades of clinical and research experience, and Dr. Ashay Karpe, a hemato-oncologist with 23 years of experience in hematological malignancies, cellular therapies, and stem cell transplantation.

SunAct's core differentiator is its proprietary metronomic chemotherapy protocols — low-dose oral regimens developed in-house by the co-founders that reportedly match or exceed standard intravenous chemotherapy efficacy at under 1% of the cost, with low-dose immunotherapy reducing treatment cost by more than 90%. These protocols have reportedly entered clinical practice guidelines. The company's go-to-market is hospital-based professional services, with revenue generated through direct patient consultations and treatment delivery at its two Mumbai-area facilities. Patient acquisition combines physician referrals, the founders' established clinical reputations (including ASCO oral presentations and Tata Memorial Centre Gold Medals), digital presence across Instagram, YouTube, LinkedIn, and Facebook, and a website-based consultation booking system supported by a toll-free number. Pricing is quote-based and not publicly disclosed, varying by therapy type and patient-specific requirements.

The business operates as a founder-led private limited company with no disclosed institutional investors, parent company, or external capital. No patents, trademarks, API products, or technology integrations are disclosed. SunAct has established a parallel charitable arm (SunAct Charitable Foundation) to extend treatment access, and has received formal recognition including the Centre of Excellence Award for Cell & Gene Therapy (2024) and presentations at ASCO (2022, 2024) and the Purbanchal Cancer Hospital Oration (2025). Geographic operations are entirely domestic (India), with no international service delivery disclosed despite international academic engagement.

Name

SunAct

Legal name

SunAct Cancer Private Limited

Website

https://sunactcancer.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

SunAct is a privately held Indian specialty cancer center that delivers advanced cellular and immunotherapy services — including CAR T-cell therapy, bone marrow transplantation, and proprietary low-cost metronomic chemotherapy — to hematology and oncology patients through two hospital facilities in Thane and Khar, Mumbai.

Ownership category

akta.pro rank

Product category

Cancer Treatment Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

Keywords

• Cancer treatment services
• CAR T-cell therapy
• Bone marrow transplantation
• Immunotherapy services
• Pediatric oncology

Headquarters

HQ city

Thane

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Healthcare Services Revenue: Revenue generated from providing advanced cancer therapies and medical consultations to patients at their hospital facilities in Thane and Khar, Mumbai. Services include CAR T-cell therapy, BMT, immunotherapy, targeted therapy, chemotherapy, and pediatric oncology services.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

SunAct is an advanced cancer therapy provider operating hospital facilities in Thane and Khar, Mumbai, India. The company delivers a comprehensive suite of hematological and oncological treatments including CAR T-cell therapy, bone marrow and stem cell transplantation, immunotherapy, targeted therapy, chemotherapy, and pediatric hematology-oncology services. Treatment is delivered in specialized facilities with isolation rooms designed for advanced cellular therapies, supported by proprietary cost-effective protocols developed by the founding oncologists.

Product overview

SunAct is a specialized cancer treatment center offering advanced hematological and oncological therapies at facilities in Thane and Khar, Mumbai. The company provides a comprehensive suite of cancer treatment services centered around six core offerings: Advanced Cellular Therapies (CAR T-cell therapy), Bone Marrow and Stem Cell Transplantation (BMT), Immunotherapy, Targeted Therapy, Chemotherapy, and Pediatric Services. These services are delivered through state-of-the-art hospital facilities with specialized isolation rooms for transplants and advanced treatments. The company is co-founded by Dr. (Prof.) Vijay Patil and Dr. Ashay Karpe, both leading oncologists with extensive clinical and research experience.

Differentiator

Problem solved

Functional benefit

Products and services

• Advanced Cellular Therapies (CAR T) CAR T-cell therapy — an advanced cellular immunotherapy that reprograms the patient's own immune cells to target and destroy cancer cells. Intended for cancer patients with hematological malignancies and solid tumors requiring personalized cell-based treatment.
• BMT / Stem Cell Transplantation Bone Marrow and Stem Cell Transplantation procedures that replace damaged or destroyed bone marrow with healthy stem cells. Intended for cancer patients requiring hematopoietic stem cell transplantation, including hematological malignancies.
• Immunotherapy Cancer immunotherapy treatments that harness and enhance the body's own immune system to fight cancer, including proprietary low-dose immunotherapy regimens developed by the co-founders. Intended for cancer patients seeking immune-based treatment approaches.
• Targeted Therapy Precision cancer treatments that target specific genes, proteins, or pathways that drive cancer growth and spread. Intended for patients with specific cancer types amenable to targeted molecular intervention.
• Chemotherapy Standard chemotherapy treatments using cytotoxic drugs to kill or slow the growth of cancer cells, including proprietary metronomic chemotherapy protocols (double and triple metronomic regimens). Intended for cancer patients requiring cytotoxic drug-based treatment.
• Pediatric Services (Hematology, Oncology, BMT & Cellular Therapy) Specialized comprehensive cancer care for pediatric patients including hematology, oncology, bone marrow transplant, and cellular therapy services. Intended for children requiring specialized hematology and oncology care.

Quantifiable outcome

• Low-dose immunotherapy regimen reduced treatment costs by more than 90%
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Regional players

• KIMS Healthcare (Kerala Institute of Medical Sciences): Regional multi-specialty hospital group in South India with oncology and BMT services; comparable in offering mix though geographically focused away from SunAct's Mumbai base.

Broad incumbents

• Max Healthcare: National multi-specialty hospital operator with established oncology services including BMT, immunotherapy and chemotherapy, overlapping with SunAct's treatment categories across the Delhi-NCR and Mumbai corridors.
• Medanta (The Medicity): Large multi-specialty tertiary hospital group operating dedicated cancer institute with advanced oncology, BMT and cellular therapy capabilities, competing in the Indian tertiary oncology space.
• Tata Memorial Hospital: India's flagship government specialty cancer hospital and the alma mater of SunAct's co-founders; provides comprehensive oncology including BMT and is the country's reference center for advanced therapies, anchoring clinical credibility and training pipelines.
• Apollo Hospitals (Cancer Care Division): Largest Indian private hospital chain with dedicated oncology centers offering BMT, immunotherapy, targeted therapy and precision oncology across multiple cities, representing a key competitive incumbent in advanced cancer care.
• Fortis Healthcare: Large multi-specialty hospital chain operating oncology programs across India with BMT and targeted therapy offerings, competing for the same advanced-cancer patient pool as SunAct in Mumbai and beyond.

Direct peers

• HealthCare Global Enterprises (HCG): India's largest dedicated oncology hospital network providing medical, surgical, and radiation oncology plus BMT and precision medicine across 20+ centers, directly competing in advanced cancer care delivery.
• Rajiv Gandhi Cancer Institute and Research Centre: Specialty cancer hospital in Delhi-NCR offering comprehensive oncology services including BMT and advanced therapies, comparable to SunAct as a standalone non-chain specialty oncology center.
• Cytecare Cancer Hospitals: Indian specialty cancer hospital chain offering medical oncology, surgical oncology, BMT, and advanced therapies including cellular treatments, with a multi-city footprint comparable in scope and patient focus to SunAct.
• Mazumdar Shaw Medical Centre (Narayana Health): Specialty oncology hospital in Bangalore within Narayana Health, offering advanced cancer therapies including BMT and cellular therapy—a comparable Indian specialty cancer delivery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@SunAct_socials
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/sunact
• Instagraminstagram.com/sunact_advacedcancertherapies

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SunAct